Concert Pharmaceuticals Inc. (NASDAQ:CNCE) has been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the firm. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $23.17.

Several research firms recently commented on CNCE. Zacks Investment Research upgraded Concert Pharmaceuticals from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research report on Thursday, November 10th. Roth Capital set a $32.00 price target on Concert Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, October 28th. Brean Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Concert Pharmaceuticals in a research note on Wednesday, September 7th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $23.00 price target on shares of Concert Pharmaceuticals in a research note on Tuesday, September 27th.

Concert Pharmaceuticals (NASDAQ:CNCE) opened at 9.86 on Wednesday. The stock has a 50 day moving average price of $9.13 and a 200-day moving average price of $10.83. The firm’s market capitalization is $219.62 million. Concert Pharmaceuticals has a 12-month low of $7.50 and a 12-month high of $23.96.

Concert Pharmaceuticals (NASDAQ:CNCE) last posted its earnings results on Tuesday, November 8th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.12. Concert Pharmaceuticals had a negative return on equity of 33.68% and a negative net margin of 363.29%. On average, equities research analysts forecast that Concert Pharmaceuticals will post ($2.36) EPS for the current year.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Advisors LLC raised its stake in Concert Pharmaceuticals by 2.2% in the second quarter. BlackRock Advisors LLC now owns 71,332 shares of the company’s stock valued at $801,000 after buying an additional 1,509 shares in the last quarter. Vanguard Group Inc. raised its stake in Concert Pharmaceuticals by 4.1% in the second quarter. Vanguard Group Inc. now owns 606,359 shares of the company’s stock valued at $6,809,000 after buying an additional 23,885 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Concert Pharmaceuticals by 3.3% in the second quarter. Dimensional Fund Advisors LP now owns 328,467 shares of the company’s stock valued at $3,689,000 after buying an additional 10,452 shares in the last quarter. Nationwide Fund Advisors raised its stake in Concert Pharmaceuticals by 0.9% in the second quarter. Nationwide Fund Advisors now owns 37,420 shares of the company’s stock valued at $420,000 after buying an additional 322 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its stake in Concert Pharmaceuticals by 1.4% in the second quarter. PNC Financial Services Group Inc. now owns 51,109 shares of the company’s stock valued at $574,000 after buying an additional 708 shares in the last quarter. 60.75% of the stock is owned by institutional investors and hedge funds.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386.

5 Day Chart for NASDAQ:CNCE

Receive News & Stock Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.